|
Drug Topics
Hospital
Pharmacists' Report
DrugTopics.com
October 6, 2011 |
CLINICAL NEWS
The Institute for Safe Medication Practices is warning pharmacists and other healthcare providers about reported mix-ups of Durezol, a prescription eyedrop solution, and Durasal, a prescription wart remover. » More |
|
Blue Shield of California will no longer pay for the use of bevacizumab (Avastin, Genentech) to treat metastatic breast cancer. » More |
ADVERTISEMENT
Resource Center: Oral Anticoagulation in Atrial Fibrillation
Atrial fibrillation afflicts more than 2.3 million persons in the United States and is expected to increase 2.5-fold by 2050. To find risk stratifying tools and articles on emerging oral anticoagulant therapies, click here. |
|
Children with diabetes may have a higher-than-average rate of asthma, and those with both conditions seem to have a tougher time keeping their blood sugar under control, a recent study suggests. » More |
FDA ACTIONS
FDA recently approved clindamycin injection, USP (Sagent Pharmaceuticals/Strides Arcolab), an antibiotic used to treat bacterial infections. » More |
PAIN MANAGEMENT
The American Pain Foundation recently released survey results showing that 17% of adults with chronic pain who have tried to reach their primary pain-care providers with questions face difficulties doing so. » More |
DRUG SUPPLY
FDA and other regulatory and international partners recently completed the International Internet Week of Action. This year’s operation focused on websites that purvey illegal and dangerous medications. » More |
|
Johnson & Johnson has reported that a limited supply of doxorubicin (Doxil) will become available within the next 6 weeks, but the company warned that the amount would not be sufficient for all patients currently on waiting lists. » More |
E-TOOLS
A collaboration of healthcare leaders and organizations, known as AF Stat: A Call to Action for Atrial Fibrillation, recently released the AFib Educator 2.0, a free smartphone app and desktop widget. » More |
|
Healthcare professionals now have 2 new online tools to help them compare the effectiveness, benefits, and harmful effects of different treatment options. » More |
|
Confirm your
e-newsletter subscription click here.
To ensure future delivery of email newsletters from Drug Topics please take a moment to confirm your subscription by clicking here.
Thank you,
Drug Topics Staff |
Digital Edition |
|
|
|
You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.
To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
|
